BTK as a novel diagnostic biomarker and therapeutic target in osteosarcoma.

BACKGROUND

Osteosarcoma is the most common malignant bone tumor in adolescents with a poor prognosis. So far, there is still a lack of effective molecular biomarkers for early diagnosis and effective therapeutic targets for osteosarcoma. Bruton tyrosine kinase (BTK) is reported to be overexpressed in various tumors and may be present as an independent prognostic biomarker. The functions of BTK in osteosarcoma are still unclear. Thereby, our study is devoted to investigating the status of BTK in the progression of osteosarcoma.

METHODS

An immunohistochemistry (IHC) assay was used to detect the expression of BTK in osteosarcoma tissues. Cell count kit-8 (CCK-8), cell colony, transwell, transcriptome sequencing, Western blot and xenograft model assays were applied to analyze osteosarcoma biological function changes after blocking by the BTK inhibitor (Ibrutinib).

RESULTS

The findings showed that BTK is high expressed in osteosarcoma tissues, and high BTK expression predicts poor survival outcome in osteosarcoma patients. Blocking of BTK by Ibrutinib can partially suppress the proliferation, migration, invasion, tumor growth and lung metastasis in osteosarcoma via the NF-κB signaling pathway.

CONCLUSIONS

Our present study suggested that BTK may present as a proto-oncogene in the progression of osteosarcoma, and inhibiting BTK expression can partially suppress the progression of osteosarcoma via the NF-κB signaling pathway.